Patents Examined by Michael G. Hartley
  • Patent number: 10688201
    Abstract: A method of synthesizing a radiolabeled nanoparticle. The method includes heating a solution including an iron oxide nanoparticle and at least one radioactive metal ion to bind the iron oxide nanoparticle and the at least one radioactive metal ion, thereby forming the radiolabeled nanoparticle. The method further includes adding a quenching agent to the solution to complex with non-bound radioactive metal ions remaining in the solution. The method further includes separating the complexed quenching agent from the radiolabeled nanoparticle.
    Type: Grant
    Filed: October 9, 2014
    Date of Patent: June 23, 2020
    Assignee: The General Hospital Corporation
    Inventors: Jason Philip Holland, Lee Josephson
  • Patent number: 10688200
    Abstract: The present invention relates to compounds according to Formula I and Formula IV. These compounds display very good binding affinities to the PSMA binding sites. They can be labeled with [68Ga]GaCl3 with high yields and excellent radiochemical purity. The present invention also relates to pharmaceutical compositions comprising a pharmaceutical acceptable carrier and a compound of Formula I or Formula IV, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: December 20, 2016
    Date of Patent: June 23, 2020
    Assignee: FIVE ELEVEN PHARMA INC.
    Inventors: Hank F. Kung, Karl Ploessl, Seok Rye Choi, Zhihao Zha, Zehui Wu
  • Patent number: 10689415
    Abstract: Conjugates of porphyrin, chlorophyll and bacteriochlorophyll photosensitizers with RGD-containing peptides or RGD peptidomimetics are provided that are useful for photodynamic therapy (PDT), particularly vascular-targeted PDT (VTP), of tumors and nonneoplastic vascular diseases such as age-related macular degeneration, and for diagnosis of tumors by different techniques.
    Type: Grant
    Filed: April 19, 2018
    Date of Patent: June 23, 2020
    Assignee: YEDA RESEARCH AND DEVELOPMENT CO. LTD.
    Inventors: Avigdor Scherz, Yoram Salomon, Efrat Rubinstein, Alexander Brandis, Doron Eren, Karin Neimann
  • Patent number: 10688199
    Abstract: Provided is a theranostic bubble preparation which makes it possible to diagnose and treat a tissue of interest by the irradiation with ultrasound such as diagnostic ultrasound and low-intensity therapeutic ultrasound. The theranostic bubble preparation comprises: a coating film comprising a lipid; and a gas enclosed in an inner cavity formed in the coating film. The coating film comprises an anionic lipid made from distearoylphosphatidylcholine (DSPC), distearoylphosphatidylglycerol (DSPG) and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (DSPE-PEG2000). The gas and the mixed gas comprises perfluoropropane or perfluorobutane.
    Type: Grant
    Filed: June 10, 2016
    Date of Patent: June 23, 2020
    Assignee: TEIKYO UNIVERSITY
    Inventors: Kazuo Maruyama, Ryo Suzuki, Johan Mikael Unga, Daiki Omata, Yusuke Oda
  • Patent number: 10688040
    Abstract: The present invention includes a construct that comprises at least one microbubble encapsulated within the aqueous core of a microcapsule. The present invention also includes a pharmaceutical composition comprising a construct comprising at least one microbubble encapsulated within the aqueous core of a microcapsule. The present invention further includes a method of imaging a tissue or organ in a subject, a method of delivering a therapeutic cargo to a tissue or organ in a subject, and a method of treating a disease or disorder in a subject.
    Type: Grant
    Filed: March 4, 2019
    Date of Patent: June 23, 2020
    Assignee: Drexel University
    Inventors: Steven P. Wrenn, Stephen Dicker
  • Patent number: 10688198
    Abstract: Salicylic acid-based polymeric CEST contrast agents targeting prostate-specific membrane antigen, pharmaceutical composition comprising the same and methods of use thereof are disclosed.
    Type: Grant
    Filed: September 29, 2016
    Date of Patent: June 23, 2020
    Assignee: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Sangeeta Ray, Xing Yang, Xiaolei Song, Michael T. McMahon, Martin G. Pomper
  • Patent number: 10682421
    Abstract: There is disclosed a composition in the form of a nanoparticle. The nanoparticle composition has a diameter from 5 to 500 nanometers. The nanoparticle composition has i) a central core portion including magnetic Fe3O4 nanoparticles adapted to act as a heat source when subjected to a magnetic field and a chemotherapeutic agent configured to treat cancer tissues, ii)—a shell portion including a shell member encapsulating said core portion, and iii)—antibodies configured to target cancer stem cells and adhered to surface of said shell member. The chemotherapeutic agent is a heat shock protein inhibitor and is releasable on activation of the heat source due to the magnetic field, and the shell member is made of silica or a silica based material.
    Type: Grant
    Filed: March 8, 2018
    Date of Patent: June 16, 2020
    Assignee: CITY UNIVERSITY OF HONG KONG
    Inventors: Mengsu Yang, Dandan Liu
  • Patent number: 10682429
    Abstract: Suspension of gas-filled microvesicles comprising a targeting ligand for binding to KDR or VEGF/KDR complex. The suspension is obtained by reconstituting a freeze-dried residue with a carbohydrate-containing solution in the presence of a physiologically acceptable gas and is stabilized by the presence of histidine.
    Type: Grant
    Filed: December 17, 2015
    Date of Patent: June 16, 2020
    Assignee: BRACCO SUISSE S.A.
    Inventors: Philippe Bussat, Anne Lassus
  • Patent number: 10683272
    Abstract: Low-molecular weight gadolinium (Gd)-based MR contrast agents for PSMA-specific Ti-weighted MR imaging are disclosed. The (Gd)-based MR contrast agents exhibit high binding affinity for PSMA and exhibit specific Ti contrast enhancement at PSMA+ cells. The PSMA-targeted Gd-based MR contrast agents can be used for PSMA-targeted imaging in vivo. 86Y-labeled PSMA-binding ureas also are provided, wherein the PSMA-binding ureas also are suitable for use with other radiotherapeutics.
    Type: Grant
    Filed: May 6, 2015
    Date of Patent: June 16, 2020
    Assignees: THE JOHNS HOPKINS UNIVERSITY, NORTHWESTERN UNIVERSITY
    Inventors: Sangeeta Ray, Martin G. Pomper, Thomas J. Meade, Ronnie C. Mease, Ying Chen, Xing Yang, Matthew Rotz
  • Patent number: 10684294
    Abstract: Provided herein are improved fluorogenic compounds and probes that can be used as reagents for measuring, detecting and/or screening hypochlorous acid or hydroxyl radical. The fluorogenic compounds of the invention can produce fluorescence colors, such as green, yellow, red, or far-red. Also provided herein are fluorogenic compounds for selectively staining hypochlorous acid or hydroxyl radical in the mitochondria of living cells. Provided also herein are methods that can be used to measure, directly or indirectly, the presence and/or amount of hypochlorous acid or hydroxyl radical in chemical samples and biological samples such as cells and tissues in living organisms. Also provided are high-throughput screening methods for detecting or screening hypochlorous acid or hydroxyl radical or compounds that can increase or decrease the level of hypochlorous acid or hydroxyl radical in chemical and biological samples.
    Type: Grant
    Filed: April 22, 2016
    Date of Patent: June 16, 2020
    Assignee: THE UNIVERSITY OF HONG KONG
    Inventors: Dan Yang, Jun Hu, Nai-Kei Wong, Xiaoyu Bai
  • Patent number: 10675367
    Abstract: The present invention relates to deuterated and optionally detectably labeled compounds of formula (I) and formula (V): and salts thereof, wherein R1, R2, A, and X10-X19 have any of the values defined in the specification. Also included are pharmaceutical compositions comprising such compounds and salts, and methods of using such compounds and salts as imaging agents.
    Type: Grant
    Filed: July 31, 2018
    Date of Patent: June 9, 2020
    Assignee: Genentech Inc.
    Inventors: Jan Marik, Joseph P. Lyssikatos, Simon Williams
  • Patent number: 10675364
    Abstract: The present disclosure encompasses embodiments of a novel near-infrared-emitting molecular fluorophore and probes incorporating said fluorophore advantageous for in vitro and in vivo research studies. The fluorophore is robust, photostable, and possesses functionalities for easy bioorthogonal conjugation (e.g., click chemistry, hydrazone formation, Diels Alder, Staudinger ligation, etc.). It is biocompatible and emits at 711 nm in aqueous conditions. These fluorophores may be used to fluorescently tag biological molecules or structures of interest, or used as optical reporters (i.e., activatable molecular probes, fluorescent dyes) for specific biomarkers/analytes as they can be switched from “off” to “on.” This fluorophore is useful for cellular assays and preclinical small animal imaging as the near-infrared emission is highly penetrating, and the photophysical properties are outstanding. As such, the properties of this class of fluorophores could easily be translated for use in clinical applications.
    Type: Grant
    Filed: June 23, 2016
    Date of Patent: June 9, 2020
    Assignees: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY, THE CURATORS OF THE UNIVERSITY OF MISSOURI
    Inventors: Kenneth Hettie, Jessica Klockow, Timothy Glass, Frederick T. Chin
  • Patent number: 10675365
    Abstract: The present invention relates to a curcumin derivative, a method for producing same, and a photo-acoustic imaging agent comprising the curcumin derivative for detecting beta-amyloid plaque. The curcumin derivative, expressed by chemical formula 1, according to the present invention exhibits superb selective bonding with beta-amyloid, thereby allowing beta-amyloid to be detected by means of an optical or photo-acoustic imaging methods, and, particularly, the curcumin derivative can highly effectively detect photo-acoustic signals with almost no noise by reacting to irradiation of light having a particular wavelength range, and thus can be useful as a composition for detecting beta-amyloid and for diagnosing diseases caused by excessive production of beta-amyloid.
    Type: Grant
    Filed: September 29, 2016
    Date of Patent: June 9, 2020
    Assignee: Korea Atomic Energy Research Institute
    Inventors: Yong-Dae Park, Jung-Joon Min, Seung-Dae Yang, Min-Goo Hur, Seung-Jin Jung, Yeong-Jin Hong, Seung-Hwan Park
  • Patent number: 10675366
    Abstract: The present disclosure provides a positron emission tomography (PET)-detectable 1-((2-fluoro-6-[18F]fluorophenyl)sulfonyl)-4-((4-methoxyphenyl)sulfonyl)piperazine ([18F]DASA-23) probe that can selectively bind to the pyruvate kinase variant M2 (PKM2) found in cancer cells, such as of human glioma. Given the importance of PKM2 in the regulation of tumor metabolism, there is an on-going need to non-invasively measure its expression through the development of PKM2-specific radiopharmaceuticals. Precursors useful for the synthesis of the radiolabeled [18F]DASA-23-PKM2-specific probe and related compounds, and their methods of synthesis, are provided. Since the half-life of the 18F isotope is approximately 110 min, it is advantageous for a practitioner to attach the radionuclide to the precursor shortly before administration. Therefore, a precursor compound suitable for receiving the radionuclide and capable of specifically binding to the PKM2 variant can be provided.
    Type: Grant
    Filed: August 11, 2017
    Date of Patent: June 9, 2020
    Assignee: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
    Inventors: Corrine Gaye Beinat, Israt Shamima Alam, Michelle L. James, Sanjiv S. Gambhir, Ananth Srinivasan
  • Patent number: 10668126
    Abstract: The present invention relates to pharmaceutical compositions for treating neoplasias in an animal or human comprised of a carrier and therapeutically effective amounts of at least one chemotherapeutic agent along with the biotherapeutic endogenous pentapeptide Met-enkephalin, referred to as opioid growth factor. Also provided are methods of treating neoplasias in an animal or human in need of such treatment, comprising the administration to the animal or human therapeutically effective amounts of a pharmaceutical composition comprised of a carrier and therapeutically effective amounts of at least one neoplasia-treating agent, such as a chemotherapeutic agent or radiation, along with opioid growth factor.
    Type: Grant
    Filed: February 21, 2005
    Date of Patent: June 2, 2020
    Assignee: The Penn State University Research Foundation
    Inventors: Ian S. Zagon, Patricia J. McLaughlin, Jill P. Smith
  • Patent number: 10670581
    Abstract: The present invention provides oxygenized nanobubbles and their uses in imaging and cancer treatment when combined with therapeutic drugs and precise ultrasound beam steering.
    Type: Grant
    Filed: March 7, 2018
    Date of Patent: June 2, 2020
    Assignee: Purdue Research Foundation
    Inventors: Joseph Irudayaraj, Pushpak Bhandari
  • Patent number: 10668174
    Abstract: A method of reducing radiation exposure of a non-cancerous tissue of a patient diagnosed with a cancer includes administering to the patient an agent capable of competing for binding sites on a surface of the non-cancerous tissue, provided that the administration is carried out after a waiting period that follows administration of a compound including a radionuclide to the patient, the compound having affinity for both a cancerous tissue and the non-cancerous tissue, and, further provided that the binding sites have an affinity for both the agent and the compound.
    Type: Grant
    Filed: March 23, 2018
    Date of Patent: June 2, 2020
    Assignee: Molecular Insight Pharmaceuticals, Inc.
    Inventors: John W. Babich, Shawn Hillier, John Joyal
  • Patent number: 10660835
    Abstract: A method directed to a hair soaking treatment for frizz reduction comprising immersion of consumer hair into an aqueous composition is disclosed. A method for hair frizz reduction wherein hair is soaked for at least about 2 minutes in an aqueous composition having a viscosity of less than about 1000 cP comprising from about 0.
    Type: Grant
    Filed: April 2, 2015
    Date of Patent: May 26, 2020
    Assignee: The Procter and Gamble Company
    Inventors: Supriya Punyani, Jennifer Mary Marsh, James Charles Dunbar, Curtis Bobby Motley, Lisa Jo Bartz, Erica Vencil Buckner
  • Patent number: 10660976
    Abstract: Among the various aspects of the present disclosure is the provision of compositions and methods for imaging and treating subjects with amyloidosis or multiple myeloma with or without amyloidosis.
    Type: Grant
    Filed: November 6, 2018
    Date of Patent: May 26, 2020
    Assignee: Washington University
    Inventor: Vijay Sharma
  • Patent number: 10660974
    Abstract: Dioxetane-based chemiluminescence probes, more specifically fluorophore-tethered dioxetane-based chemiluminescence probes and ?* acceptor group-containing dioxetane based chemiluminescence probes can be included in compositions. The chemiluminescence probes are useful for both diagnostics and in vivo imaging.
    Type: Grant
    Filed: January 24, 2017
    Date of Patent: May 26, 2020
    Assignee: RAMOT AT TEL-AVIV UNIVERSITY LTD.
    Inventors: Doron Shabat, Ronit Satchi-Fainaro, Nir Hananya, Ori Green, Tal Eilon